• 1
    Correll CU, Druss BG, Lombardo I et al. Findings of a U.S. national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatr Serv 2010;61:892-8.
  • 2
    Druss BG, Zhao L, Von Esenwein S et al. Understanding excess mortality in persons with mental illness: 17-year follow up of a nationally representative US survey. Med Care 2011;49:599-604.
  • 3
    De Hert M, Correll CU, Bobes J et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011;10:52-77.
  • 4
    Stroup TS, McEvoy JP, Ring KD et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011;168:947-56.
  • 5
    Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 2011;68:609-16.
  • 6
    Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
  • 7
    Brunner EJ, Rees K, Ward K et al. Dietary advice for reducing cardiovascular risk. Cochrane Database Syst Rev 2007;4:CD002128.
  • 8
    Ali MK, Echouffo-Tcheugui JB, Williamson DF. How effective were lifestyle interventions in real-world settings that were modeled on the Diabetes Prevention Program? Health Affairs 2012;31:67-75.
  • 9
    Daumit GL, Dickerson FB, Wang NY et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med 2013;368:1594-602.
  • 10
    Bartels S, Desilets R. Health promotion programs for people with serious mental illness (prepared by the Dartmouth Health Promotion Research Team). Washington: SAMHSA-HRSA Center for Integrated Health Solutions, 2012.
  • 11
    Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311:74-86.
  • 12
    Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010;35:1520-30.
  • 13
    Jarskog LF, Hamer RM, Catellier DJ et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry 2013;170:1032-40.
  • 14
    Imfeld P, Bodmer M, Jick SS et al. Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study. J Am Geriatr Soc 2012;60:916-21.
  • 15
    Vest AR, Heneghan HM, Agarwal S et al. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart 2012;98:1763-77.
  • 16
    Ahmed AT, Warton EM, Schaefer CA. The effect of bariatric surgery on psychiatric course among patients with bipolar disorder. Bipolar Disord 2013;15:753-63.